Introduction
Cancer is the second leading cause of death in the developed world, accounting in 2004 for over half a million deaths. Cancers at four organ sites -lung/bronchus, colorectal, breast and prostate -accounted for 56% of all cancer cases and 53% of all cancer deaths [1] . Approximately half of patients diagnosed with cancer will develop metastatic disease. Over 70% of all cancer patients develop symptoms from either their primary or metastatic disease [2] . The overall metastatic burden and the number and location of the sites involved by disease influence prognosis. There is an increasing surgical intervention rate in cancer patients, both for primary tumour excision and emergency intervention for intercurrent illness. Coupled with the increased use of chemotherapeutic agents over the past decade, cancer patients requiring surgery present particular challenges for the anaesthetist [2] . This review outlines acute perioperative care for cancer patients. Early research reports suggest a possible association between perioperative anaesthetic technique and cancer outcome. Chronic pain management of cancer patients, and acute cancer pain management outside the context of the postoperative period, is beyond the scope of this work.
Systemic effects of cancer and metastasis
Pain is one of the most common and feared symptoms associated with cancer. It occurs in 25% of patients with newly diagnosed malignancies, and in 75% of those with advanced disease [3] .
Measurable psychological distress and depression affects up to 70% of all oncology patients. Interest has increased in the role that psychological distress may play in complicating the presentation, treatment and prognosis of patients with cancer [4] .
Approximately half of all cancer patients develop cachexia [5] , characterized by anorexia, weight loss, weakness, poor performance and impaired immune function [6] .
Adequate vascular access is required for effective administration of chemotherapeutic agents, blood products, nutritional support and the multiple blood tests needed for monitoring cancer patients [7] . Central line insertion may be difficult in patients with cancer because of coagulopathy, multiple previous attempts in the same vessels, or difficulty in placing patients supine where there is respiratory distress.
Cardiac side effects of cancer therapy provide a considerable challenge to the clinician. Arrhythmias, radiationinduced myocardial ischemia, congestive heart failure, anthracycline and radiation-induced cardiomyopathy, peripheral vascular disease and pericardial disease can all be caused by different cancer therapies [8] .
It is estimated that 5-10% of patients taking chemotherapy may experience an adverse pulmonary reaction. The clinical syndrome of radiation pneumonitis develops in 5-20% of all irradiated patients. Factors that increase the incidence of lung toxicity include concomitant administration of oxygen, radiation therapy, IV route of administration, going above an established cumulative threshold dose, pre-existing respiratory morbidity and advanced age [9] .
Mechanisms of renal failure include pre-renal failure secondary to inadequate renal perfusion from feverinduced dehydration or cardiac failure. Intrinsic renal failure in the cancer setting may result from generalized sepsis syndrome or nephrotoxic therapy, including antibiotics. Urinary obstruction commonly occurs with locally advanced pelvic cancers, for example, prostate and cervical cancers [10] .
Neutropenia is common in cancer patients either because the malignant process interferes with bone marrow function or because chemotherapeutic regimens administered to treat the disease cause myelosuppression. Since the neutrophil is an important host defence against many pathogens, neutropenic patients are at increased risk of developing opportunistic infection. The frequency of infectious complications is related to the degree and duration of neutropenia [11] .
Infection in hospitalized oncology patients poses a serious challenge and may lead to unfavourable impact on successful cancer treatment outcomes. In addition, nosocomial infections are well recognized predictors of prolonged hospital stay and increased cost [12] .
More than 75% of patients receiving combination chemotherapy are affected [13] . The chemoreceptor trigger zone, located in the area postrema at the ventral aspect of the fourth ventricle, can be stimulated by drugs including opiates, anaesthetic agents, and cancer chemotherapy. Metabolic abnormalities, for example, uraemia, hypoxia and ketoacidosis, may also cause nausea and vomiting.
Acute abdomen or bowel obstruction, bleeding and fistula formation can present as emergent surgical problems in cancer patients [14] .
Hypercalcaemia (serum calcium >2.7 mmol/l) is the major metabolic abnormality seen in malignant disease: it occurs in approximately 10% of all cancer patients [15] . It is most commonly seen in squamous cell carcinoma of the bronchus in the absence of bony metastasis, suggesting a humoral factor in its aetiology. Breast cancer causes excessive calcium mobilization from bone in the presence of multiple osseous metastasis, and multiple myeloma is associated with local bone destruction and abnormal renal function [15] .
Hyponatraemia (serum sodium >145 mmol/l) results from an impaired ability to excrete a water load, due to inability to produce dilute urine. Arginine vasopressin activity is increased in patients with hyponatraemia of malignancy [16] . Syndrome of inappropriate antidiuretic hormone (SIADH) is the most common cause of hyponatraemia among cancer patients. Neoplasms associated with SIADH are small cell carcinoma of lung, and carcinoma of the pancreas, bladder, prostate, breast and colon.
Tumour lysis syndrome (TLS) is a spectrum of metabolic derangement usually associated with the cytotoxic therapy of malignancy. It is characterized by numerous metabolic abnormalities (including hyperuricemia, hyperphosphatemia, hypocalcaemia, hyperkalaemia and uraemia) and frequently leads to acute renal failure. Malignancies associated with TLS are acute and chronic lymphoid and myeloid leukaemia, small cell carcinoma of the lung, and testicular and breast cancers [17] .
Haematological problems
Anaemia tends to increase in severity as the stage of the disease progresses. Malignancy-associated anaemia is designated as an anaemia of chronic disease. Serum erythropoietin levels are inappropriately low for a given level of anaemia in patients with cancer. It is possible that erythropoietin-producing cells are either directly suppressed by the malignancy itself or that these cells are functionally impaired by chemotherapy or radiation therapy [18] .
Leukopenia is associated with cytotoxic treatment in 20-50% of patients with solid tumours. The probability of clinical infection is proportional to its severity and duration [19] .
Thrombocytopenia in cancer patients is usually attributable to chemotherapy and radiation therapy. However, thrombocytopenia may also be due to splenic sequestration in patients in whom splenomegaly is part of the primary neoplastic process [20] .
The incidence of thrombosis is 2-10% of all patients with cancer. Most thrombotic complications occur postoperatively. Thrombosis can be the first symptom of an occult malignancy. Patients with adenocarcinoma are at increased risk [20] .
Local effects of cancer and metastases
Superior vena cava syndrome may occur as an acute or subacute process with characteristic features including facial oedema, plethora, dilatation of chest wall and neck veins, respiratory difficulty, conjunctival oedema, headache, visual disturbance and altered states of consciousness. Diagnosis is based on clinical findings. It is usually due to a neoplastic obstruction of venous return from the head and neck, primary lung carcinoma being the most prominent [21] .
Spinal cord compression is diagnosed in more than 30% of all patients with disseminated cancer. Back pain virtually always precedes neurological injury. It has a devastating impact on quality of life and is frequently diagnosed late. The presence of new or worsening back pain in a patient with cancer should be a clarion call to action, including MRI scan and spinal decompression surgery [22] .
Systemic effects of cancer therapy
During recent decades, the number of anticancer drugs has grown dramatically, paralleled by an increasing number of patients receiving such therapy. Chemotherapeutic agents are intended to selectively destroy neoplastic cells by interfering with a metabolic pathway not present in normal cells [23] . Often there are significant negative side effects including nausea, vomiting, hair loss, anorexia, fatigue, peripheral neuropathy and anaemia. It has been estimated that 33% of patients undergoing systemic chemotherapy have cognitive dysfunction that interferes with their quality of life [24] . Various anticancer drugs may be associated with different organ toxicity, as outlined in Table 1 [25, 26] .
Radiotherapy has replaced surgery for the long-term control of many tumours of the head and neck, cervix, bladder, prostate and skin, in which it often achieves reasonable tumour control with good cosmetic results. In addition, many patients gain valuable palliation by radiation [27] . Whenever radiation therapy is given with curative intent, there is the risk of serious damage to normal tissues.
With modern megavoltage equipment, epidermal reactions are usually limited to dry desquamation and increased pigmentation. Late changes are characterized by atrophy leading to contraction of the irradiated area [28] .
Acute mucositis frequently occurs, with clinical symptoms such as diarrhoea or gastritis.
The nervous system is less sensitive to radiation injury than other tissues such as the lung or kidney. Radiationinduced peripheral neuropathy is characterized by mixed sensory and motor deficits, developing after a latent period [28] .
In the lungs, fibrosis from radiation therapy may develop late, for example, after 2-6 months. Clinical signs or symptoms of acute radiation pneumonitis are reduced pulmonary compliance, progressive dyspnoea and dry cough.
In the kidney, radiation nephropathy usually manifests as proteinuria, hypertension and impairment in urine concentration. Angiotensin converting enzyme (ACE) inhibitors or angiotensin II antagonists may significantly ameliorate radiation nephropathy [28] .
In the heart, the most common type of radiation-induced injury is pericarditis with a pericardial effusion, which occurs within 6 months to 2 years. It is often asymptomatic.
In the liver, two phases of radiation hepatopathy are recognized. The acute phase develops approximately 2-6 weeks after irradiation, with liver enlargement and portal hypertension (ascites). Liver function tests are abnormal. The chronic phase occurs 6 months-1 year post-irradiation, and shows progressive cirrhotic changes [28] .
Anticancer drugs and interaction with anaesthetics
Most studies on interactions between anticancer chemotherapeutic agents and anaesthetic substances have been in vitro. A significant inhibitory effect on tumour growth in cell lines was observed when cytostatics and anaesthetics were given concomitantly. Lidocaine enhanced bleomycin-induced cytotoxicity and deoxyribonucleic acid (DNA) damage. A 50% reduction in lethal dose for methotrexate was observed, when it was combined with nitrous oxide, probably due to the synergistic inhibitory effects of nitrous oxide and methotrexate on folate metabolism [29] .
Symptomatic cancer therapy and anaesthetics
Propofol was safely used during a 4-week course of radiation therapy in patients with Hodgkin's disease who required daily anaesthesia for treatment [30] . The antiemetic effect of propofol was therapeutic in patients with nausea and vomiting secondary to cisplatin chemotherapy [31] . Intravenous midazolam rapidly relieved intractable hiccup in cancer patients [32] .
Anaesthetic considerations in the cancer patient
There are a number of factors to be considered for the cancer patient.
Preoperative assessment
Determining the risks associated with a given surgical operation in a cancer patient is a complex process based Anaesthesia for cancer patients Arain and Buggy 249 on a number of factors. The physical status of the patient, including nutritional assessment and comorbid conditions, morbidity inherent to a specific operation and the goal of surgery are all relevant. The assessment should balance the risk associated with disease progression and those associated with treatment [33] . The preoperative cancer patient is frequently in relatively poor physical condition. Patients often present with poor nutritional status, considerable pain, physiologic abnormalities (e.g. electrolyte disorders), and significant comorbid conditions. Nutritional deficiencies should be corrected prior to surgery if possible with hyperalimentation or total parenteral nutrition. Consideration should be given to replenishing depleted blood volume if major blood loss is anticipated, and correcting electrolyte abnormalities prior to major surgical resections.
Physiological status related to cardiopulmonary reserve and hepatic and renal function should also be assessed and optimized. The underlying disease, as well as the procedure itself, must be considered in the preoperative risk assessment [33] . Involvement of the heart by primary malignancy, metastatic disease or anticancer treatment has important implications. Patients with a history of cardiotoxicity should undergo echocardiography. Further cardiac evaluation such as stress testing and angiography should be considered in specific conditions [33] .
Several endocrine system disorders can have a major impact on perioperative morbidity and mortality. These include diabetes mellitus, diabetes insipidus, hypopituitarism, thyroid disorders, abnormalities of adrenal cortex and medullary function, and calcium disorders. Failure to identify these disorders in the preoperative period can lead to acute medical problems in the intraoperative or postoperative periods [34] . Prior cancer therapy and its potential complications are also important aspects of preoperative assessment. Although it may be preferable to anaesthetize patients only after any coexisting medical conditions have been successfully mitigated, some cancer operations, while not true emergencies, cannot wait excessively for interventions that could delay surgery and allow cancer to spread. Appropriate support may be necessary if organ damage is critical or expected to worsen after surgery.
Identification of correctable causes of anaemia, leuopoenia and thrombocytopenia, and appropriate therapy, including replacement of blood elements, bone marrow stem cell stimulation and maintenance of coagulation homeostasis, improve patient's survival [34] .
Assessment of preoperative nutritional status and planning for perioperative support merit attention [35] . Studies assessing nutrition in cancer patients suggest a reduction in infectious complications, protein catabolism, and inflammatory markers with preoperative or early postoperative feeding.
Further investigations should be undertaken at the discretion of the attending anaesthetist as indicated, following a thorough history and physical examination. For major procedures in most cancer patients, laboratory studies should include a complete blood count, serum electrolyte, liver function tests, and coagulation profile. A 12-lead electrocardiogram may be advisable [35] . Chest radiograph should not be conducted routinely unless there is a specific clinical indication.
Intraoperative management
The published standards for basic anaesthetic monitoring should be applied. Additional monitoring should be deployed as indicated to maintain physiologic homeostasis or to provide early warning of worsening organ system function and to direct appropriate interventions. Temperature monitoring should be routine, because inadvertent perioperative hypothermia is associated with a number of deleterious consequences, such as wound infections, morbid cardiac events and increased blood loss [36] . Forced convective air-warming devices actively heat patients during anaesthesia and aim to restore normothermia.
Cancer patients with tumour involving head, neck, and mediastinum may present with established or potential airway compromise. Assessment of the airway by physical examination and appropriate imaging is of paramount importance. Awake fiberoptic intubations should be the technique of choice for large head and neck tumours where there is a risk of airway compromise on induction of general anaesthesia. Elective tracheostomy should be considered where fiberoptic intubation is deemed impossible or hazardous, for example, large nasopharyngeal tumour. Continuing postoperative endotracheal intubation is often prudent until airway patency is assured [37] .
Perioperative blood component therapy should be guided by clinical judgement, considering the benefits and risks of such therapy. Cytomegalovirus infection has been a substantial cause of morbidity and mortality in oncology patients who are immunocompromised.
Patients at risk are those who received allogenic bone marrow/stem cell transplantation. Guidelines for blood transfusion recommend that blood should not be transfused prophylactically and suggest that in patients without risk factors, the threshold for transfusion should be a haemoglobin level of 6-8 g/dl, whereas a threshold of 10-11 g/dl can be justified for patients who are considered at risk [38] . Thrombocytopenia remains a significant clinical problem for patients with cancer. Although platelet transfusion remains the gold standard for prophylaxis and treatment of thrombocytopenia, transfusiontransmitted disease, infection and platelet refractoriness are associated with its use [39] .
Benzodiazepines are increasingly recognized as having immunomodulatory actions mediated via the central nervous system. There are some data to suggest that cytokines released in response to surgical stress may be reduced by midazolam [40] . Clinical concentration of nitrous oxide and enflurane transiently depress natural killer-cell activity [41] . However, there is no evidence to support the use of one volatile anaesthetic agent over another. Thiopentone decreases neutrophil chemotaxis, while etomidate inhibits basal cortisol production, abolishes the stress response and increases mortality from wound infection in trauma patients admitted to intensive care [42] . Intraoperatively, high dose fentanyl (in the order of 20 mg/kg) and morphine suppress natural killer-cell activity for 24-48 h [43] .
There are no studies evaluating the influence of anaesthetic technique on cancer outcome. However, experimental studies from Ben-Eliyahu and colleagues demonstrated that rats injected with a breast cancer cell line had decreased metastases when the animals had a laparotomy under regional anaesthesia compared with general anaesthesia [44] . Further work using this model suggested that optimizing analgesia after surgery could also reduce metastatic spread of the cancer [45] . A recent retrospective study in breast cancer patients who received paravertebral anaesthesia with a general anaesthetic or general anaesthesia alone found that paravertebral anaesthesia was associated with a 79% decrease in the incidence of recurrence or metastases 3-4 years later [46] . A similar retrospective study in men who had radical prostatectomy under general anaesthetic with morphine analgesia compared with general anaesthetic and epidural analgesia combined found that the epidural technique was associated with a 65% reduction in biochemical recurrence of prostate cancer (defined by increased Prostate Specific Antigen postoperatively) [47] . These observations suggest that prospective randomized trials comparing cancer outcome in patients who have, or have not, received regional anaesthesia as a part of their perioperative care for primary cancer surgery, are warranted.
Postoperative pain management
Chronic cancer pain and its management often confound the effective perioperative management of acute pain. Drug tolerance and disordered nociception present therapeutic challenges in cancer patients. Using a standard equianalgesia conversion table to convert the patient's opioids into parenteral dose equivalents per hour may be helpful. Continuing opioids throughout the perioperative period and titrating them to clinical responsiveness intraoperatively may also be indicated, bearing in mind that tolerance is commonly present. The presence of tolerance may necessitate frequent and higher dosing. Adequate doses of opioids should be provided with at least an additional 30% for the acute postoperative period [48, 49] .
Conclusion
Optimum perioperative care of the cancer patient requires assessment of the impact of cancer and its treatment on the functional reserve of all major organ systems in the individual patient. Although various anaesthetic agents and surgery itself have important effects on immune function, their clinical significance is not well established. Available evidence suggests that anaesthetic agents have short-term reversible effects on host immunity, and there is as yet no evidence to suggest that one anaesthetic technique is associated with better outcomes in cancer patients.
